Literature DB >> 26004675

MRI and oxidative stress markers in neurological worsening of Wilson disease following penicillamine.

A Ranjan1, J Kalita2, V Kumar1, U K Misra1.   

Abstract

BACKGROUND AND AIM: There is no report of MRI correlation with neurological worsening following chelating treatment in Wilson disease with neurological manifestation (WDN). We report radiological changes in four patients with WDN who worsen after penicillamine.
METHODS: WDN was diagnosed on the basis of clinical, KF ring, serum ceruloplasmin and 24h urinary copper. Hematological, biochemical and cranial MRI were repeated at the time of clinical deterioration following chelating treatment.
RESULTS: Four WDN patients had neurological deterioration within 4-8 weeks of penicillamine therapy. This was associated with new lesions in white matter, thalamus, pons and mid brain and these lesions showed diffusion restriction. The neurologic deterioration was associated with increased free serum copper and malanodialdehyde and reduced glutathione. Clinical conditions stabilized after few weeks of penicillamine discontinuation.
CONCLUSION: Neurological worsening was associated with new lesions on MRI which revealed diffusion restriction. Increased free copper induced oxidative stress may be responsible for these changes.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  MRI; Penicillamine; Trientine; Wilson disease; Worsening

Mesh:

Substances:

Year:  2015        PMID: 26004675     DOI: 10.1016/j.neuro.2015.05.004

Source DB:  PubMed          Journal:  Neurotoxicology        ISSN: 0161-813X            Impact factor:   4.294


  9 in total

1.  Wilson's disease: A review of what we have learned.

Authors:  Kryssia Isabel Rodriguez-Castro; Francisco Javier Hevia-Urrutia; Giacomo Carlo Sturniolo
Journal:  World J Hepatol       Date:  2015-12-18

2.  Memory and Learning Dysfunction Following Copper Toxicity: Biochemical and Immunohistochemical Basis.

Authors:  Jayantee Kalita; Vijay Kumar; Usha K Misra; Himangsu K Bora
Journal:  Mol Neurobiol       Date:  2017-05-23       Impact factor: 5.590

3.  Role of Oxidative Stress in the Worsening of Neurologic Wilson Disease Following Chelating Therapy.

Authors:  Jayantee Kalita; Vijay Kumar; Abhay Ranjan; Usha K Misra
Journal:  Neuromolecular Med       Date:  2015-07-30       Impact factor: 3.843

Review 4.  [Diagnostics of Wilson's disease].

Authors:  W Hermann; D Huster
Journal:  Nervenarzt       Date:  2018-02       Impact factor: 1.214

5.  Persistence with medical treatment for Wilson disease in China based on a single center's survey research.

Authors:  Zhi-Hua Zhou; Yun-Fan Wu; Yan Yan; Ai-Qun Liu; Qing-Yun Yu; Zhong-Xing Peng; Gong-Qiang Wang; Ming-Fan Hong
Journal:  Brain Behav       Date:  2021-05-05       Impact factor: 2.708

6.  Chemosensitivity of U251 Cells to the Co-treatment of D-Penicillamine and Copper: Possible Implications on Wilson Disease Patients.

Authors:  Meghri Katerji; Kassem Barada; Mustapha Jomaa; Firas Kobeissy; Ahmad-Kareem Makkawi; Wassim Abou-Kheir; Julnar Usta
Journal:  Front Mol Neurosci       Date:  2017-01-31       Impact factor: 5.639

Review 7.  Advances in Treatment of Wilson Disease.

Authors:  Annu Aggarwal; Mohit Bhatt
Journal:  Tremor Other Hyperkinet Mov (N Y)       Date:  2018-02-28

8.  Switching Pharmacological Treatment in Wilson Disease: Case Report and Recommendations.

Authors:  Marcia Leung; Jaimie Wu Lanzafame; Valentina Medici
Journal:  J Investig Med High Impact Case Rep       Date:  2020 Jan-Dec

9.  Clinical and Genetic Analysis in Neurological Wilson's Disease Patients With Neurological Worsening Following Chelator Therapy.

Authors:  Haiman Hou; Dingbang Chen; Junxiu Liu; Li Feng; Jiwei Zhang; Xiuling Liang; Yuming Xu; Xunhua Li
Journal:  Front Genet       Date:  2022-04-04       Impact factor: 4.772

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.